Study design
neutropenia, neuropathy, toxicity, toxicities, liver abnormalities, rash, GI toxicity
THROMBOCYTOPENIA, NEUTROPENIA, NEUROPATHY
Patients were treated using a 3 + 3 dose confirmation strategy for eribulin with dose expansion at the MTD. Cyclophosphamide was given at a fıxed dose of 600 mg/mDrug doses were modified for treatment-related toxicity. These toxicities were neutropenia (absolute neutrophil count [ANC] < 1000/μL), thrombocytopenia, rash, GI toxicity, liver abnormalities and neuropathy. If toxicity occurred in a patient, dose reductions were managed as follows. Dose levels -1 and -2 for eribulin were 1.1 mg/m